Table 1. Frequency of clinicopathological characteristics in all breast cancer patients according to p-eIF2α expression.
| Characteristics | n | p-eIF2α |
P | |
|---|---|---|---|---|
| Low | High | |||
| Age (years) | 0.451 | |||
| <50 | 87 | 32(36.8%) | 55(63.2%) | |
| ≥50 | 146 | 61(41.8%) | 85(58.2%) | |
| Menopausal status | 0.467 | |||
| Pre | 126 | 53(42.1%) | 73(57.9%) | |
| Post | 107 | 40(37.4%) | 67(62.6%) | |
| Pathological subtype | 0.073 | |||
| IDC | 204 | 77(37.7%) | 127(62.3%) | |
| Others | 29 | 16(55.2%) | 13(44.8%) | |
| Histological grade | 0.425 | |||
| Low | 124 | 49(39.5%) | 75(60.5%) | |
| High | 86 | 32(37.2%) | 54(62.8%) | |
| Unknown | 23 | 12(52.2%) | 11(47.8%) | |
| Stage | 0.392 | |||
| I and II | 182 | 70(38.5%) | 112(61.5%) | |
| III | 51 | 23(45.1%) | 28(54.9%) | |
| Tumor size | 0.686 | |||
| ≤2 cm | 61 | 23(37.7%) | 38(62.3%) | |
| 2–5 cm | 121 | 47(38.8%) | 74(61.2%) | |
| >5 cm | 51 | 23(45.1%) | 28(54.9%) | |
| Node status | 0.039 | |||
| Negative | 127 | 43(33.9%) | 84(66.1%) | |
| Positive | 106 | 50(47.2%) | 56(52.8%) | |
| LVI | 0.127 | |||
| Negative | 149 | 54(36.2%) | 95(63.8%) | |
| Positive | 84 | 39(46.4%) | 45(53.6%) | |
| ER status | 0.852 | |||
| Negative | 116 | 47(40.5%) | 69(59.5%) | |
| Positive | 117 | 46(39.3%) | 71(60.7%) | |
| PR status | 0.608 | |||
| Negative | 128 | 53(41.4%) | 75(58.6%) | |
| Positive | 105 | 40(38.1%) | 65(61.9%) | |
| HER-2 status | 0.519 | |||
| Negative | 147 | 61(41.5%) | 86(58.5%) | |
| Positive | 86 | 32(37.2%) | 54(62.8%) | |
| Ki67 status | 0.707 | |||
| <20% | 94 | 38(40.4%) | 56(59.6%) | |
| ≥20% | 80 | 34(42.5%) | 46(57.5%) | |
| Unknown | 59 | 21(35.6%) | 38(64.4%) | |
| Molecular subtype | 0.458 | |||
| Luminal | 84 | 38(45.2%) | 46(54.8%) | |
| Her2+ | 86 | 32(37.2%) | 54(62.8%) | |
| Triple-negative | 63 | 23(36.5%) | 40(63.5%) | |
| Chemotherapy | 0.267 | |||
| Doxorubicin based | 124 | 55(44.4%) | 69(55.6%) | |
| Taxanes added | 82 | 26(31.7%) | 56(68.3%) | |
| CMF or Xeloda | 6 | 2(33.3%) | 4(66.7%) | |
| None | 21 | 10(47.6%) | 11(52.4%) | |
| Radiotherapy | 0.703 | |||
| No | 157 | 64(40.8%) | 93(59.2%) | |
| Yes | 76 | 29(38.2%) | 47(61.8%) | |
Abbreviations: IDC = invasive ductal carcinoma; Low histological grade = 1 or 2, high histological grade = 3; LVI = lymphatic vascular invasion; ER = estrogen receptor; PR = progesterone receptor; Her2 = human epidermal growth factor receptor-2; Luminal represents Luminal A or Luminal B breast cancer patients; Her2+ represents Her2/Luminal B or Her2+ breast cancer patients. CMF: Cyclophosphamide, Methotrexate and 5-Fluorouracil.